drugset / Trial / NCT07210450

Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia

NCT07210450

Phase 2/3 Completed 8 enrolled Mazandaran University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to learn whether L-glutamine can help lower pulmonary artery pressure in adults with non-transfusion-dependent thalassemia (NTDT). The main questions it aims to answer are: Does L-glutamine reduce pulmonary artery pressure after 60 days of treatment? Is the effect of L-glutamine different from standard care alone? Researchers will compare two groups: Intervention group: Participants receive oral L-glutamine in addition to their standard treatment. Control group: Participants continue with standard treatment only. Participants will: Take either L-glutamine (by mouth) or standard care for 60 days. Undergo echocardiography at the beginning and end of the study to measure pulmonary artery pressure. Attend follow-up visits to monitor safety, adherence, and possible side effects.

Timeline

Start
2023-08-15
Primary completion
2025-05-22
Completion
2025-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Glutamine Other / unclassified 0.1 g/kg Oral

Indications